Aurion Biotech launches Vyznova in Japan

USA and Japan based privately held company Aurion Biotech has announced the commercial launch of Vyznova (neltependocel) in Japan, for the treatment of bullous keratopathy of the cornea.

The company says it believes this is the first approved cell therapy for the treatment of corneal endothelial disease; it has received both regulatory and reimbursement approval in Japan. The commercial launch was inaugurated with cell therapy procedures performed by Professor Shigeru Kinoshita at Kyoto Prefecture University of Medicine (KPUM) in Kyoto, Japan.

Professor Kinoshita pioneered the research and development of corneal endothelial cell therapy, and the proprietary process for propagating corneal endothelial cells in vitro. Several years ago, Aurion Biotech acquired the technology from Kinoshita and KPUM, and the company has continued to innovate by scaling the manufacture of fully differentiated, allogeneic human corneal endothelial cells, the active moiety of Vyznova.